CN105209017A - 用于癌症疗法的脂质体顺铂组合物 - Google Patents

用于癌症疗法的脂质体顺铂组合物 Download PDF

Info

Publication number
CN105209017A
CN105209017A CN201480026589.0A CN201480026589A CN105209017A CN 105209017 A CN105209017 A CN 105209017A CN 201480026589 A CN201480026589 A CN 201480026589A CN 105209017 A CN105209017 A CN 105209017A
Authority
CN
China
Prior art keywords
liposome
compositions
cisplatin
peg
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480026589.0A
Other languages
English (en)
Chinese (zh)
Inventor
W·麦吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Mallinckrodt LLC
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of CN105209017A publication Critical patent/CN105209017A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CN201480026589.0A 2013-03-13 2014-03-13 用于癌症疗法的脂质体顺铂组合物 Pending CN105209017A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780272P 2013-03-13 2013-03-13
US61/780,272 2013-03-13
PCT/US2014/026341 WO2014160337A1 (en) 2013-03-13 2014-03-13 Liposomal cisplatin compositions for cancer therapy

Publications (1)

Publication Number Publication Date
CN105209017A true CN105209017A (zh) 2015-12-30

Family

ID=50439522

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480026589.0A Pending CN105209017A (zh) 2013-03-13 2014-03-13 用于癌症疗法的脂质体顺铂组合物

Country Status (8)

Country Link
US (2) US10039716B2 (enExample)
EP (1) EP2968142A1 (enExample)
JP (1) JP6077710B2 (enExample)
CN (1) CN105209017A (enExample)
BR (1) BR112015022415A2 (enExample)
CA (1) CA2903254C (enExample)
MX (1) MX2015012199A (enExample)
WO (1) WO2014160337A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108136217A (zh) * 2016-01-07 2018-06-08 健康科学西部大学 用于治疗膀胱癌的制剂
US12491158B2 (en) 2020-03-10 2025-12-09 Chung Yuan Christian University Liposome composition and preparation method thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5994049B2 (ja) * 2012-10-01 2016-09-21 兵神装備株式会社 吐出システム
WO2016141161A1 (en) * 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
US20170049701A1 (en) * 2015-08-05 2017-02-23 Steven M. Kushner Clustoidal multilamellar soy lecithin phospholipid structures for transdermal, transmucosal, or oral delivery, improved intestinal absorption, and improved bioavailability of nutrients
WO2017053464A1 (en) * 2015-09-21 2017-03-30 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
WO2017142876A1 (en) 2016-02-15 2017-08-24 University Of Georgia Research Foundation, Inc. lPA-3-LOADED LIPOSOMES AND METHODS OF USE THEREOF
AU2017268175B2 (en) 2016-05-16 2023-02-23 Access To Advanced Health Institute PEGylated liposomes and methods of use
SG10202107836SA (en) * 2017-01-18 2021-08-30 Temasek Life Sciences Laboratory Ltd Hyperstabilized liposomes increase targeting of mitotic cells
WO2019094648A1 (en) 2017-11-08 2019-05-16 L.E.A.F. Holdings Group Llc Platinum complexes and uses thereof
TW202345843A (zh) * 2022-04-06 2023-12-01 財團法人國家衛生研究院 脂質奈米顆粒及脂質體

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1396822A (zh) * 2000-01-28 2003-02-12 阿尔萨公司 含有存在于过饱和溶液中的包载化合物的脂质体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US20020009488A1 (en) * 1995-05-03 2002-01-24 Polymasc Pharmaceuticals Plc Tissue entrapment
WO1998007409A1 (en) * 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
BR9815445A (pt) 1997-02-05 2001-09-25 Pharmacia & Upjohn Spa Complexos lipìdicos e lipossomas de complexos de platina altamente insolúveis
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
EP1448165B1 (en) * 2001-11-13 2007-09-19 Celator Pharmaceuticals, Inc. Lipid carrier compositions and methods for improved drug retention
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1716870A1 (en) * 2005-04-29 2006-11-02 Bracco Imaging S.p.A. MRI contrast agents endowed with concentration independent responsiveness
US20100034874A1 (en) 2006-12-08 2010-02-11 Katayama Chemical Industries Co., Ltd. Liposome encapsulating ammine-platinum complex at high concentration, and method for production of the liposome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1396822A (zh) * 2000-01-28 2003-02-12 阿尔萨公司 含有存在于过饱和溶液中的包载化合物的脂质体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108136217A (zh) * 2016-01-07 2018-06-08 健康科学西部大学 用于治疗膀胱癌的制剂
CN108136217B (zh) * 2016-01-07 2021-04-30 健康科学西部大学 用于治疗膀胱癌的制剂
US12491158B2 (en) 2020-03-10 2025-12-09 Chung Yuan Christian University Liposome composition and preparation method thereof

Also Published As

Publication number Publication date
US20140271821A1 (en) 2014-09-18
WO2014160337A1 (en) 2014-10-02
MX2015012199A (es) 2015-11-30
US10039716B2 (en) 2018-08-07
US20180318219A1 (en) 2018-11-08
JP2016513651A (ja) 2016-05-16
CA2903254C (en) 2019-04-09
US10383823B2 (en) 2019-08-20
CA2903254A1 (en) 2014-10-02
EP2968142A1 (en) 2016-01-20
BR112015022415A2 (pt) 2017-07-18
JP6077710B2 (ja) 2017-02-08

Similar Documents

Publication Publication Date Title
CN105209017A (zh) 用于癌症疗法的脂质体顺铂组合物
CA2903234C (en) Liposome oxaliplatin compositions for cancer therapy
US9717686B2 (en) Combinational liposome compositions for cancer therapy
CA2903255C (en) Modified docetaxel liposome formulations
US20180344644A1 (en) Improved stability of liposome formulations and uses thereof
EP3380082A2 (en) Drug formulations for cancer treatment
WO2014092858A1 (en) Compositions and methods for treatment of cancer
US20160250177A1 (en) Modified docetaxel liposome formulations and uses thereof
US20230330025A1 (en) Particle Modifiers for Multi-Drug Loaded Nanoparticles
US20210290537A1 (en) Liposomal elinafide formulations and uses thereof
US20200079785A1 (en) Mitomycin c prodrug liposome formulations and uses thereof
WO2025034562A1 (en) Proliposomes and compositions, methods of making, and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20201127